1. Same-day trial of void and discharge following standard vs. MOSES holmium laser enucleation of the prostate: A single-center experience
- Author
-
Yasser Noureldin, Aurinjoy Gupta, Amr Hodhod, Ahmed S. Zakaria, Ruba Abdul Hadi, Vahid Mehrnoush, Loay Abbas, Moustafa Fathy, Amer Alaref, Ahmed Kotb, Walid Shahrour, and Hazem Elmansy
- Subjects
Oncology ,Urology - Abstract
Introduction: We aimed to compare perioperative and postoperative outcomes and to assess the safety and feasibility of same-day trial of void (TOV) in patients who underwent standard holmium laser enucleation of the prostate (HoLEP) vs. MOSESTM HoLEP (MoLEP). Methods: We conducted a retrospective review of prospectively collected data of patients that underwent HoLEP (100 W) or MoLEP (120 W) with same-day catheter removal three hours postoperatively at our institution from August 2018 to September 2021. Patient demographics, intraoperative parameters, and postoperative outcomes were analyzed. Data were compared as means with standard deviation and medians with interquartile range (IQR) or numbers and percentages. Continuous and categorical variables were assessed using the Mann-Whitney U test and Chi-squared test, respectively. Predictors of shorter enucleation time and failed same-day TOV were investigated. Results: Of the 90 patients included, 28 underwent HoLEP while 62 had MoLEP. There was no significant difference between the groups in terms of the successful TOV (23 [82%] vs. 58 [93.5%], p=0.1) and readmission rate (3 [10.7%] vs. 1 [1.6%], p=0.08); however, the MoLEP group had a significantly shorter mean enucleation time (p
- Published
- 2022
- Full Text
- View/download PDF